Evidence map›Paper›PMID 34203627›Full record

ReviewInternational journal of molecular sciences2021

Endothelial Progenitor Cell-Derived Extracellular Vesicles: Potential Therapeutic Application in Tissue Repair and Regeneration.

Sonia Terriaca, Elena Fiorelli, Maria Giovanna Scioli, Giulia Fabbri, Gabriele Storti, Valerio Cervelli, Augusto Orlandi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Endothelial Progenitor Cells: Disease Markers and Potential Therapy in Kidney Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sonia TerriacaDepartment of Biomedicine and Prevention, Anatomic Pathology Institute, University of Rome Tor Vergata, 00133 Rome, Italy.
Elena FiorelliDepartment of Biomedicine and Prevention, Anatomic Pathology Institute, University of Rome Tor Vergata, 00133 Rome, Italy.
Maria Giovanna ScioliDepartment of Biomedicine and Prevention, Anatomic Pathology Institute, University of Rome Tor Vergata, 00133 Rome, Italy.
Giulia FabbriDepartment of Biomedicine and Prevention, Anatomic Pathology Institute, University of Rome Tor Vergata, 00133 Rome, Italy.
Gabriele StortiPlastic and Reconstructive Surgery, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Valerio CervelliPlastic and Reconstructive Surgery, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Augusto OrlandiDepartment of Biomedicine and Prevention, Anatomic Pathology Institute, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7202-5854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, many studies investigated the role of a specific type of stem cell named the endothelial progenitor cell (EPC) in tissue regeneration and repair. EPCs represent a heterogeneous population of mononuclear cells resident in the adult bone marrow. EPCs can migrate and differentiate in injured sites or act in a paracrine way. Among the EPCs' secretome, extracellular vesicles (EVs) gained relevance due to their possible use for cell-free biological therapy. They are more biocompatible, less immunogenic, and present a lower oncological risk compared to cell-based options. EVs can efficiently pass the pulmonary filter and deliver to target tissues different molecules, such as micro-RNA, growth factors, cytokines, chemokines, and non-coding RNAs. Their effects are often analogous to their cellular counterparts, and EPC-derived EVs have been tested in vitro and on animal models to treat several medical conditions, including ischemic stroke, myocardial infarction, diabetes, and acute kidney injury. EPC-derived EVs have also been studied for bone, brain, and lung regeneration and as carriers for drug delivery. This review will discuss the pre-clinical evidence regarding EPC-derived EVs in the different disease models and regenerative settings. Moreover, we will discuss the translation of their use into clinical practice and the possible limitations of this process.

Indexed as

Organ SpecificityAnimalsEndothelial Progenitor CellsExtracellular VesiclesHumansRegenerationWound Healingendothelial progenitor cellsextracellular vesiclesinjuryrecipient cellstissue regeneration

Identifiers

PMID34203627
PMCPMC8232313

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.